Advanced Solid Tumors
36 competing products in clinical development for Advanced Solid Tumors.
Pipeline by Phase
Phase 129
Phase 1/24
Phase 23
All Products (36)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| ASP1570 + pembrolizumab + Trifluridine + Tipiracil + Bevacizumab + Docetaxel + Oxaliplatin + Leucovorin + 5-Fluorouracil + Irinotecan + Pemetrexed + Carboplatin | Astellas Pharma | Phase 1/2 | Recruiting | 39 |
| ASP1002 | Astellas Pharma | Phase 1 | Recruiting | 36 |
| linsitinib + erlotinib + paclitaxel + Bortezomib + Dexamethasone | Astellas Pharma | Phase 2 | Completed | 35 |
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | Completed | 35 |
| Gilteritinib | Astellas Pharma | Phase 1/2 | Completed | 32 |
| Mogamulizumab (KW-0761) | Kyowa Kirin | Phase 1/2 | Completed | 32 |
| IMC-18F1 | Eli Lilly | Phase 1 | Completed | 29 |
| DS-8201a (DP1) + DS-8201a (DP2) + DS-8201a (DP) | Daiichi Sankyo | Phase 1 | Completed | 29 |
| Pexidartinib | Daiichi Sankyo | Phase 1 | Completed | 29 |
| OSI-906 + erlotinib | Astellas Pharma | Phase 1 | Completed | 29 |
| OSI-906 | Astellas Pharma | Phase 1 | Completed | 29 |
| radio-labeled OSI-906 + OSI-906 | Astellas Pharma | Phase 1 | Completed | 29 |
| OSI-930 + OSI-930 | Astellas Pharma | Phase 1 | Completed | 29 |
| OSI-930 and erlotinib | Astellas Pharma | Phase 1 | Completed | 29 |
| ASP1948 + nivolumab + pembrolizumab | Astellas Pharma | Phase 1 | Completed | 29 |
| Tarceva, erlotinib, OSI-774 | Astellas Pharma | Phase 1 | Completed | 29 |
| ASP8374 + Pembrolizumab | Astellas Pharma | Phase 1 | Completed | 29 |
| OSI-906 | Astellas Pharma | Phase 1 | Completed | 29 |
| gilteritinib + 14C-labeled gilteritinib | Astellas Pharma | Phase 1 | Completed | 29 |
| ASP8374 | Astellas Pharma | Phase 1 | Completed | 29 |
| E7820 + E7820 | Eisai | Phase 1 | Completed | 29 |
| Lenvatinib | Eisai | Phase 1 | Completed | 29 |
| E7389 | Eisai | Phase 1 | Completed | 29 |
| E6201 | Eisai | Phase 1 | Completed | 29 |
| eribulin | Eisai | Phase 1 | Completed | 29 |
| mogamulizumab + MEDI4736 (Durvalumab) + tremelimumab | Kyowa Kirin | Phase 1 | Completed | 29 |
| ONO-4538 | Ono Pharmaceutical | Phase 1 | Completed | 29 |
| ONO-4538 | Ono Pharmaceutical | Phase 1 | Completed | 29 |
| Golvatinib + Lenvatinib + Lenvatinib | Eisai | Phase 1/2 | Terminated | 24 |
| U3-1784 | Daiichi Sankyo | Phase 1 | Terminated | 21 |
| ASP2074 | Astellas Pharma | Phase 1 | Terminated | 21 |
| ASP1951 + pembrolizumab | Astellas Pharma | Phase 1 | Terminated | 21 |
| OKI-179 | OnKure Therapeutics | Phase 1 | Completed | 19 |
| SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent) | Syros Pharmaceuticals | Phase 1 | Terminated | 11 |
| mRNA-4359 | Moderna | Phase 2 | Recruiting | 0 |
| mRNA-4106 | Moderna | Phase 1 | Active | 0 |